This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
Filter documents Clear search
Statement from the Royal College of Obstetricians & Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare and the British Society of Abortion Care Providers (BSACP) regarding the advent of telemedical abortion care and the safeguarding of young people.
Recent media reports have highlighted cases of individuals who have experienced distressing intrauterine contraception (IUC) fitting. Read and download the FSRH statement on pain associated with intrauterine contraception.
This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.
Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.
This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).
This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.
FSRH CEU Response to study: Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme inducing antibiotics and hormonal contraceptives - February 2021
This statement is a response to a new paper published in BMJ Evidence Based Medicine Journal suggesting that antibiotics may lessen the effectiveness of hormonal contraception.
FSRH Clinical Effectiveness Unit Statement: Use of combined hormonal contraception during the Covid-19 pandemic - Dec 2020
This FSRH CEU Statement considers the risk of thromboembolism associated with Covid-19 infection, and suggests a pragmatic approach to use of combined hormonal contraception during the Covid-19 pandemic
FSRH CEU Statement: Response to recently published “Bridge-It” study by Cameron, et al - November 2020
The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.
“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.